CNS Pharmaceuticals Announces Acceptance of Abstract for Poster Presentation at the 2024 SNO/ASCO CNS Cancer Conference
CNS Pharmaceuticals (NASDAQ:CNSP) has announced that its abstract has been accepted for a poster presentation at the 2024 SNO/ASCO CNS Cancer Conference in Denver, CO. The presentation, titled 'Use of a Brain-Penetrating Anthracycline in Anthracycline-Sensitive Brain Metastases: The Promise of Berubicin', will be delivered by Dr. Sandra Silberman, the company's Chief Medical Officer. The poster falls under the category of Research Methods and Trial Design Considerations and is scheduled for August 8, 2024, from 7:15 - 9:00 PM MT in the Plaza Exhibit Hall of the Sheraton Denver Downtown Hotel.
CNS Pharmaceuticals (NASDAQ:CNSP) ha annunciato che il suo abstract è stato accettato per una presentazione poster alla Conferenza SNO/ASCO sul Cancro CNS 2024 che si svolgerà a Denver, CO. La presentazione, intitolata 'Uso di un Antiacido Penetrante nel Cervello nelle Metastasi Cerebrali Sensibili ad Antiacidi: La Promessa di Berubicina', sarà effettuata dalla Dott.ssa Sandra Silberman, Direttore Medico dell'azienda. Il poster rientra nella categoria dei Metodi di Ricerca e delle Considerazioni sul Design degli Studi e sarà programmaticamente presentato l'8 agosto 2024, dalle 19:15 alle 21:00 MT, nella Plaza Exhibit Hall del Sheraton Denver Downtown Hotel.
CNS Pharmaceuticals (NASDAQ:CNSP) ha anunciado que su resumen ha sido aceptado para una presentación en poster en la Conferencia sobre Cáncer CNS SNO/ASCO 2024 en Denver, CO. La presentación, titulada 'Uso de una Antraciclina que Penetra en el Cerebro en Metástasis Cerebrales Sensibles a Antraciclinas: La Promesa de Berubicina', será presentada por la Dra. Sandra Silberman, Directora Médica de la compañía. El poster se clasifica dentro de los Métodos de Investigación y consideraciones sobre el Diseño de Ensayos y está programado para el 8 de agosto de 2024, de 7:15 a 9:00 PM MT, en la Plaza Exhibit Hall del Hotel Sheraton Denver Downtown.
CNS Pharmaceuticals (NASDAQ:CNSP)는 자사의 초록이 2024 SNO/ASCO CNS 암 컨퍼런스에서 포스터 발표로 수락되었다고 발표했습니다. 발표 제목은 '두뇌 침투가 가능한 안트라사이클린을 이용한 안트라사이클린 민감 두뇌 전이: 베루비신의 가능성'이며, 회사의 최고 의학 책임자인 Sandra Silberman 박사가 발표할 예정입니다. 포스터는 연구 방법 및 임상 시험 설계 고려 사항 범주에 포함되며, 2024년 8월 8일 오후 7시 15분부터 9시까지 MT에 위치한 Sheraton Denver Downtown Hotel의 Plaza Exhibit Hall에서 진행될 예정입니다.
CNS Pharmaceuticals (NASDAQ:CNSP) a annoncé que son abstract a été accepté pour une présentation sous forme de poster lors de la Conférence SNO/ASCO sur le Cancer CNS 2024 à Denver, CO. La présentation, intitulée 'Utilisation d'un Anthracycline Pénétrant dans le Cerveau pour les Métastases Cérébrales Sensibles aux Anthracyclines : La Promesse de Berubicine', sera présentée par Dr. Sandra Silberman, Directrice Médicale de l'entreprise. Le poster relève de la catégorie Méthodes de Recherche et Considérations sur la Conception des Essais et est programmé pour le 8 août 2024, de 19h15 à 21h00 MT, dans le Plaza Exhibit Hall de l'hôtel Sheraton Denver Downtown.
CNS Pharmaceuticals (NASDAQ:CNSP) hat bekannt gegeben, dass ihr Abstract für eine Posterpräsentation auf der 2024 SNO/ASCO CNS Krebs Konferenz in Denver, CO, angenommen wurde. Die Präsentation mit dem Titel 'Einsatz eines gehirngängigen Antracyclins bei antracyclinsensiblen Gehirnmetastasen: Das Versprechen von Berubicin' wird von Dr. Sandra Silberman, der medizinischen Leiterin des Unternehmens, gehalten. Das Poster fällt in die Kategorie Forschungsmethoden und Überlegungen zum Studiendesign und ist für den 8. August 2024 von 19:15 bis 21:00 Uhr MT im Plaza Exhibit Hall des Sheraton Denver Downtown Hotels geplant.
- Abstract accepted for poster presentation at a major cancer conference
- Opportunity to showcase research on brain-penetrating cancer treatment
- None.
HOUSTON, TX / ACCESSWIRE / July 25, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that its abstract has been selected for poster presentation at the 2024 SNO/ASCO CNS Cancer Conference being held August 8-10, 2024 in Denver, CO.
Details of the presentation are as follows:
Title: Use of a Brain-Penetrating Anthracycline in Anthracycline-Sensitive Brain Metastases: The Promise of Berubicin
Presenter: Sandra Silberman, MD, PhD, Chief Medical Officer of CNS Pharmaceuticals
Abstract Code: RMTD-03
Category: Research Methods and Trial Design Considerations
Date and Time: August 8, 2024 from 7:15 - 9:00 PM MT
Location: Plaza Exhibit Hall, Sheraton Denver Downtown Hotel
For more information about the event, please visit the conference website.
About CNS Pharmaceuticals, Inc.
CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The Company's lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer.
For more information, please visit www.CNSPharma.com, and connect with the Company on X, Facebook, and LinkedIn.
CONTACTS:
Investor Relations Contact
JTC Team, LLC
Jenene Thomas
833-4717-8247
CNSP@jtcir.com
SOURCE: CNS Pharmaceuticals, Inc.
View the original press release on accesswire.com
FAQ
What is the title of CNS Pharmaceuticals' (CNSP) poster presentation at the 2024 SNO/ASCO CNS Cancer Conference?
Who will be presenting CNS Pharmaceuticals' (CNSP) poster at the 2024 SNO/ASCO CNS Cancer Conference?
When and where will CNS Pharmaceuticals (CNSP) present their poster at the 2024 SNO/ASCO CNS Cancer Conference?
What is the abstract code and category for CNS Pharmaceuticals' (CNSP) poster at the 2024 SNO/ASCO CNS Cancer Conference?
